Navegando por Palavras-chave "muscle mass"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    RELATIONSHIP BETWEEN PERIPHERAL MUSCLE STRUCTURE and FUNCTION in PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH DIFFERENT NUTRITIONAL STATUS
    (Lippincott Williams & Wilkins, 2011-07-01) Malaguti, Carla [UNIFESP]; Napolis, Lara M. [UNIFESP]; Villaca, Debora [UNIFESP]; Neder, Jose A. [UNIFESP]; Nery, Luiz E. [UNIFESP]; Dal Corso, Simone [UNIFESP]; Nove Julho Univ; Universidade Federal de São Paulo (UNIFESP)
    Malaguti, C, Napolis, LM, Villaca, D, Neder, JA, Nery, LE, and Dal Corso, S. Relationship between peripheral muscle structure and function in patients with chronic obstructive pulmonary disease with different nutritional status. J Strength Cond Res 25(7): 1795-1803, 2011-The purpose of this study was to investigate the relationships between peripheral muscle structure (mass) and function (strength, endurance, and maximal aerobic capacity) in patients with chronic obstructive pulmonary disease (COPD) with different nutritional states. Thirty-nine patients (31 male) with moderate-severe COPD (63.5 +/- 7.3 [SD] years) and 17 controls (14 male; 64.7 +/- 5.5 [SD] years) underwent isokinetic (peak torque [PT]), isometric (isometric torque [IT]), and endurance strength (total work [TW]) measurements of the knee extensor muscles and a maximal cardiopulmonary exercise test to evaluate the maximal aerobic capacity (peak oxygen uptake [<(V)over dot>O-2] peak). Muscle mass (MM) was determined using dual-energy x-ray absorptiometry. Patients with COPD presented with reduced muscle function as compared with the healthy controls: PT (105.9 +/- 33.9 vs. 134.3 +/- 30.9, N.m(-1), respectively, p < 0.05), TW (1,446.3 +/- 550.8 vs. 1,792.9 +/- 469.1 kJ, respectively, p < 0.05), and <(V)over dot>(2)peak (68.1 +/- 15.1 vs. 93.7 +/- 14.5, % pred, respectively, p, 0.05). Significant relationships were found between muscle structure and function (strength and endurance) in the patient subgroup with preserved MM and in the control group: PT.MM-1(r(2) = 0.36; p = 0.01 vs. r(2) = 0.32; p = 0.01, respectively) and TW.MM-1 (r(2) = 0.32; p = 0.01 vs. r(2) = 0.22; p = 0.05, respectively). Strength corrected for mass normalized this function in both patient subgroups, whereas endurance was normalized only in the patient subgroup without muscle depletion. Maximal aerobic capacity remained reduced, despite the correction, in both patient subgroups (depleted or nondepleted) compared with the healthy controls (<(V)over dot>(2)peak.MM-1: 9.1 +/- 3.7 vs. 21.8 +/- 4.9 vs. 28.5 +/- 4.2 ml.min.kg(-1), respectively, with p < 0.01 among groups). Muscle atrophy seems to be the main determinant of strength reduction among patients with moderate-severe COPD, whereas endurance reduction seems to be more related to imbalance between oxygen delivery and consumption than to the local muscle structure itself. Peripheral MM did not constitute a good predictor for maximal aerobic capacity in this population. the main practical application of this study is to point out a crucial role for the strategies able to ameliorate cardiorespiratory and muscular fitness in patients with COPD, even in those patients with preserved MM.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Screening for muscle wasting and dysfunction in patients with chronic kidney disease
    (Nature Publishing Group, 2016) Carrero, Juan J.; Johansen, Kirsten L.; Lindholm, Bengt; Stenvinkel, Peter; Cuppari, Lilian [UNIFESP]; Avesani, Carla M.
    Skeletal muscle mass and muscle function are negatively affected by a variety of conditions inherent to chronic kidney disease (CKD) and to dialysis treatment. Skeletal muscle mass and function serve as indicators of the nutritional and clinical state of CKD patients, and low values or derangements over time are strong predictors of poor patient outcomes. However, muscle size and function can be affected by different factors, may decline at different rates, and may have different patient implications. Therefore, operational definitions of frailty and sarcopenia have emerged to encompass these 2 dimensions of muscle health, i.e., size and functionality. The aim of this review is to appraise available methods for assessment of muscle mass and functionality, with an emphasis on their accuracy in the setting of CKD patients. We then discuss the selection of reference cutoffs for defining conditions of muscle wasting and dysfunction. Finally, we review definitions applied in studies addressing sarcopenia and frailty in CKD patients and discuss their applicability for diagnosis and monitoring.